ASCO26: 5 Data Snapshots Ahead of the Year’s Biggest Cancer Drug Meeting

Why It Matters

These data signal potential shifts in standard‑of‑care regimens and could drive multi‑billion‑dollar revenue streams for the companies involved, while informing investors about the competitive landscape of ADCs, CAR‑T and cancer vaccines.

Key Takeaways

• Merck's sac‑TMT cut progression risk 65% vs Keytruda alone
• Sac‑TMT achieved >70% response rate in first‑line NSCLC
• Eli Lilly's KLN‑101 showed MRD‑negative responses in all six patients
• Pumitamig and SSGJ‑707 reported ~70% response rates in early NSCLC trials
• Merck/Moderna melanoma vaccine intismeran cut relapse risk 49% over five years

Pulse Analysis

The American Society of Clinical Oncology’s annual meeting remains the premier venue for unveiling pivotal oncology data, and this year’s pre‑meeting abstract release offers a rare glimpse into the therapeutic trends shaping the next decade. Early snapshots highlight a surge in combination strategies—antibody‑drug conjugates paired with checkpoint inhibitors, and PD‑1/VEGF dual blockade—reflecting a broader industry push to deepen responses while managing toxicity. Analysts watch these previews closely because late‑breaking results, which arrive during the conference, often set the tone for market expectations and guide investment decisions.

Merck’s sacituzumab tirumotecan (sac‑TMT) stands out as a potential game‑changer in the crowded non‑small cell lung cancer space. By delivering a 65% reduction in progression risk and a 70% objective response when combined with Keytruda, the ADC challenges emerging bispecific antibodies and underscores the growing relevance of TROP2 targeting. If the Phase 3 data confirm these early signals, Merck could secure a high‑margin, globally scalable product that competes directly with next‑generation immunotherapies, reshaping its oncology pipeline and bolstering shareholder confidence.

Beyond ADCs, the abstracts reveal parallel breakthroughs: Eli Lilly’s KLN‑101 in‑vivo CAR‑T therapy achieved MRD‑negative status in all six multiple myeloma patients, suggesting a shift toward outpatient‑friendly cell therapies that could lower treatment costs and expand access. Meanwhile, PD‑1/VEGF combos such as Akeso’s ivonescimab, BioNTech/BMS’s pumitamig, and Pfizer‑licensed SSGJ‑707 demonstrate response rates near 70%, reinforcing the viability of dual‑pathway inhibition. Finally, the five‑year follow‑up of Merck/Moderna’s intismeran melanoma vaccine, showing a 49% relapse‑risk cut and 92% five‑year survival, provides a compelling efficacy benchmark for future cancer vaccines. Collectively, these data points signal a competitive, innovation‑driven market poised for substantial revenue growth across ADCs, CAR‑T, and vaccine platforms.